Recombinant Factor C Assay a Sustainable Endotoxin Testing Solution

Recombinant factor C (rFC) assay is a synthetic equivalent of Factor C and is the first component of the horseshoe crab clotting cascade, which is activated in response to endotoxins. Moreover, the horseshoe crab blood can be collected only during a short time frame, thus limiting its supply considerably. Hence, healthcare companies in the recombinant factor C assay market are increasing their focus on rFC methods to help alleviate this challenge and improve outcomes.

Novel rFC methods are benefitting healthcare companies, as these companies can limit their reliance on animals or any other source materials. Hence, recombinant factor C assay is acquiring popularity as a sustainable solution for endotoxin testing. Such advancements have led to the growth of the recombinant factor C assay market, where the market is estimated to reach a revenue of ~US$ 28 Mn by the end of 2027. Analysts of Transparency Market Research (TMR) opine that rFC will gain recognition in the endotoxin testing industry for its accuracy and specificity, which is as good as the LAL (Limulus Amebocyte Lysate) assay.

recombinant factor c assay market infographic

To know the scope of our report Get a Sample on Recombinant Factor C Assay Market

PyroGene rFC Benefits Pharmaceutical Companies Due to Single-step Enzymatic Process

PyroGene™ recombinant factor C assay is gaining market prominence as a single-step enzymatic process as opposed to LAL assay that involves multiple procedural steps. As such, the PyroGene brand is anticipated to dictate the highest revenue as compared to EndoNext in the recombinant factor C assay market where the market is predicted to grow at a favorable CAGR of ~9% during the forecast period. Monitoring samples for contaminants play a pivotal role in pharmaceutical and medical device industries. This explains why the revenue of pharmaceutical companies is estimated to be the highest among all end users in the market landscape.

Traditional LAL testing is largely dependent on the blood of the horseshoe crab namely Limulus polyphemus. However, multiple enzymatic steps associated with LAL assay is majorly dependent on the availability of horseshoe crabs. Hence, companies in the recombinant factor C assay market are increasing their research spending in PyroGene recombinant factor C assay that can be associated with innovative software systems to gain a read-incubate-read sequence within the workflow.

Consolidated Nature of Market to Attract Attention of Healthcare Giants

LAL assays are considered as the gold standard for endotoxin testing. However, advantages of recombinant factor C assay are transforming the market landscape, which is dictated by only two major companies. Lonza Group— a leading Swiss multinational biotechnology company is increasing efforts to make its PyroGeneTM recombinant factor C assay a compendial method in Europe by collaborating with the European Pharmacopoeia. On the other hand, Hyglos GmbH— a bioMérieux company, which is a global player in in vitro diagnostics, is increasing efforts to reduce the incidence of false positives from ß-Glucan or interference due to colored or turbid samples. Thus, healthcare companies worldwide should tap opportunities in rFC, since the recombinant factor C assay market is consolidated.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies in the recombinant factor C assay market are reducing the pressure on LAL assays for innovations in monitoring samples for contaminants in pharmaceutical products. However, lack of long-term studies that validate rFC for combination testing of unknown samples, inter-laboratory, -operator, and -lot changes poses a barrier for market growth. Hence, pharmaceutical test users are increasing their efficacy in research studies to validate successful outcomes of rFC in specific products.

Effective FDA-approved Drug Builds Credibility of Healthcare Companies

Companies in the recombinant factor C assay market are gaining competitive edge over other players by introducing FDA-approved drugs using rFC. They are increasing efforts to experiment with humanized monoclonal antibodies such as galcanezumab for the prevention of migraine in adults. Novel rFC methods are being highly publicized as non-animal alternatives for the assessment of contaminating endotoxins in drugs. Though LAL is considered as the gold standard for endotoxin testing, official declarations by the FDA are validating the efficiency of PyroGene in the recombinant factor C assay market landscape. Thus, accuracy, sensitivity, and specificity of recombinant factor C assay is being considered at par with LAL methods.

recombinant factor c assay market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

Gaining FDA approval for drugs is essential in the recombinant factor C assay market. Advantages of rFC are grabbing the attention of commercial innovators in the field of recombinant technology to explore untapped business potentials.

rFC is ensuring the sustainable evolution of horseshoe crab species. However, it is still unsure whether rFC-based tests outshine LAL assays and other robust test systems. Hence, pharmaceutical test users should increase their efficacy in long-term research studies that validate the efficiency of rFC involving unknown samples and inter-laboratory, -operator, and -lot changes. They should increase research in comparative studies of rFC involving kinetic chromogenic LAL assays that help companies to boost their credibility in the market landscape.

Recombinant Factor C Assay Market: Overview

  • The global recombinant factor C assay market was valued at ~US$ 13 Mn in 2018 and is projected to expand at a considerable CAGR from 2019 to 2027. Endotoxin detection is a crucial step before the launch of pharmaceutical drugs, medical devices, and biotechnology products for human use. Recombinant factor C assay has been accepted as an alternative to LAL tests, which are widely employed for endotoxin testing. This growing acceptance as an alternative to LAL tests and its inclusion in the regulatory pharmacopoeias would contribute to the growth of the recombinant factor C assay market.   
  • Significant advantages offered by recombinant factor C assays, including cost advantages by aiding in reducing the operator risks by lowering the rate of invalid results and reduction of over 50% of the processing time as compared to the conventional microplate-based LAL tests, contribute to the growth of the recombinant factor C assays market
  • Productivity of the pharmaceutical industry has been significantly high, with an increase in the number of drugs approved annually. According to the U.S. FDA, in 2018, over 59 new drugs were approved in the U.S. Additionally, increase in demand for personalized medicine aids in the rise in the product approvals. This contributes to the growth of the recombinant factor C assays market.

Recombinant Factor C Assay Market: Segmentation

  • The global recombinant factor C assay market has been segmented based on brand, end user, and region
  • In terms of brand, the global recombinant factor C assay market has been categorized into PyroGene and EndoNext. The PyroGene brand is sub-segmented into PyroGene Bulk rFC (2,880 tests) and PyroGene rFC (192 tests). The EndoNext brand is sub-segmented into EndoZyme II, EndoZyme II GO, and EndoLisa. 
  • Based on end user, the global recombinant factor C assay market has been segregated into pharmaceutical companies, biotechnology companies, medical device companies, and contract research organizations (CROs). The pharmaceutical companies segment dominated the market in 2018, and is likely to remain dominant during the forecast period. Growth of the segment can be attributed to increase in approvals of pharmaceutical drugs globally. In addition, rise in demand for personalized medicines contributes to increase in manufacturing of pharmaceuticals, thereby leading to rise in the number of endotoxin detection tests conducted. This would contribute to the growth of the pharmaceutical companies segment in the recombinant factor C assay market.

Recombinant Factor C Assay Market: Regional Segmentation

  • In terms of region, the global recombinant factor C assay market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global recombinant factor C assay market in 2018 and the trend is expected to continue throughout the forecast period
  • The recombinant factor C assay market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period. Incorporation of recombinant factor C as a recognized endotoxin detection test by pharmacopoeias, and focus on conservation of the Limulus species in Asia Pacific contributes to the growth of the recombinant factor C assay market in the region.

Recombinant Factor C Assay Market: Major Players

  • Key players operating in the global recombinant factor C assay market are Lonza Group and Hyglos GmbH – a bioMérieux Company 
  • These players are focused on adopting inorganic growth strategies and product launches to strengthen their product portfolio. In June 2018, bioMérieux launched rapid ENDOZYME II GO, a new endotoxin test in the bioMérieux ENDONEXT range of recombinant horseshoe crab factor C assays. bioMérieux entered the market in 2016, through the acquisition of Hyglos, a company engaged in the development of recombinant factor C assays for endotoxin testing.

Global Recombinant Factor C Assay Market – Segmentation

Brand

PyroGene

  • PyroGene Bulk rFC (2,880 tests)
  • PyroGene rFC (192 tests)

EndoNext

  • EndoZyme II
  • EndoZyme II GO
  • EndoLisa

End User

Pharmaceutical Companies

Biotechnology Companies

Medical Device Companies

Contract Research Organizations (CROs)

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

Recombinant factor C assay market to reach a revenue of ~US$ 28 Mn by the end of 2027

Recombinant factor C assay market is driven by rise in need for alternative endotoxin detection tests

North America dominated the global recombinant factor C assay market in 2018 and the trend is anticipated to continue during the forecast period

The PyroGene brand segment is likely to account for a major share of the global recombinant factor C assay market during the forecast period

Key players operating in the global recombinant factor C assay market include Lonza Group and Hyglos GmbH – a bioMérieux Company

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary: Global Recombinant Factor C Assay Market

5. Market Overview

    5.1. Definition

    5.2. Market Indicators

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunities

    5.4. Global Recombinant Factor C Assay Market Revenue (US$ Mn) Forecast 2017–2027

    5.5. Global Recombinant Factor C Assay Market Outlook

6. Key Insights

    6.1. Value Chain Analysis

    6.2. Key Industry Events

    6.3. Patent Analysis

    6.4. Product Features & USPs

    6.5. Overview of Pyrogen Testing Products Market

        6.5.1. Pyrogen Testing- Service Providers

        6.5.2. Pyrogen Testing Products Marketing, by Country/Region

    6.6. Overview of Limulus Amoebocyte Lysate (LAL) Tests

        6.6.1. Number of Assays Performed

        6.6.2. Cost per Assay and Turn Around Time

    6.7. Regulatory Scenario, by Country/Region

    6.8. Institutes Involved in Research Studies using Horseshoe Crabs

7. Global Recombinant Factor C Assay Market Analysis and Forecast, by Brand 

    7.1. Introduction 

    7.2. Global Recombinant Factor C Assay Market Value Share Analysis, by Brand

    7.3. Global Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

        7.3.1. PyroGene

            7.3.1.1. PyroGene Bulk rFC (2,880 tests)

            7.3.1.2. PyroGene rFC (192 tests)

        7.3.2. EndoNext

            7.3.2.1. Endozyme II

            7.3.2.2. Endozyme II GO

            7.3.2.3. EndoLisa

    7.4. Global Recombinant Factor C Assay Market Attractiveness, by Brand 

8. Global Recombinant Factor C Assay Market Analysis and Forecast, by End-user

    8.1. Introduction 

    8.2. Global Recombinant Factor C Assay Market Value Share Analysis, by End-user

    8.3. Global Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

        8.3.1. Pharmaceutical Companies

        8.3.2. Biotechnology Companies

        8.3.3. Medical Device Companies 

        8.3.4. Contract Research Organizations (CROs)

    8.4. Global Recombinant Factor C Assay Market Attractiveness, by End-user

9. Global Recombinant Factor C Assay Market Analysis and Forecast, by Region 

    9.1. Regional Outlook

    9.2. Introduction

    9.3. Global Recombinant Factor C Assay Market Value Forecast, by Region

        9.3.1. North America

        9.3.2. Europe 

        9.3.3. Asia Pacific

        9.3.4. Latin America 

        9.3.5. Middle East & Africa

    9.4. Global Recombinant Factor C Assay Market Attractiveness, by Region

10. North America Recombinant Factor C Assay Market Analysis and Forecast

    10.1.  Key Findings

    10.2.  North America Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

        10.2.1. PyroGene

            10.2.1.1. PyroGene Bulk rFC (2,880 tests)

            10.2.1.2. PyroGene rFC (192 tests)

        10.2.2. EndoNext

            10.2.2.1. Endozyme II

            10.2.2.2. Endozyme II GO

            10.2.2.3. EndoLisa

    10.3. North America Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

        10.3.1. Pharmaceutical Companies

        10.3.2. Biotechnology Companies

        10.3.3. Medical Device Companies 

        10.3.4. Contract Research Organizations (CROs)

    10.4. North America Recombinant Factor C Assay Market Value Forecast, by Country, 2017–2027

        10.4.1. U.S.

        10.4.2. Canada

    10.5. North America Recombinant Factor C Assay Market Attractiveness Analysis

        10.5.1. By Brand

        10.5.2. By End-user

        10.5.3. By Country

11. Europe Recombinant Factor C Assay Market Analysis and Forecast

    11.1.  Key Findings

    11.2.  Europe Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

        11.2.1. PyroGene

            11.2.1.1. PyroGene Bulk rFC (2,880 tests)

            11.2.1.2. PyroGene rFC (192 tests)

        11.2.2. EndoNext

            11.2.2.1. Endozyme II

            11.2.2.2. Endozyme II GO

            11.2.2.3. EndoLisa

    11.3. Europe Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

        11.3.1. Pharmaceutical Companies

        11.3.2. Biotechnology Companies

        11.3.3. Medical Device Companies 

        11.3.4. Contract Research Organizations (CROs)

    11.4. Europe Recombinant Factor C Assay Market Value Forecast, by Country/Sub-region, 2017–2027

        11.4.1. U.K.

        11.4.2. Germany

        11.4.3. France

        11.4.4. Italy 

        11.4.5. Spain

        11.4.6. Rest of Europe

    11.5. Europe Recombinant Factor C Assay Market Attractiveness Analysis

        11.5.1. By Brand

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Asia Pacific Recombinant Factor C Assay Market Analysis and Forecast

    12.1.  Key Findings

    12.2.  Asia Pacific Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

        12.2.1. PyroGene

            12.2.1.1. PyroGene Bulk rFC (2,880 tests)

            12.2.1.2. PyroGene rFC (192 tests)

        12.2.2. EndoNext

            12.2.2.1. Endozyme II

            12.2.2.2. Endozyme II GO

            12.2.2.3. EndoLisa

    12.3. Asia Pacific Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

        12.3.1. Pharmaceutical Companies

        12.3.2. Biotechnology Companies

        12.3.3. Medical Device Companies 

        12.3.4. Contract Research Organizations (CROs)

    12.4. Asia Pacific Recombinant Factor C Assay Market Value Forecast, by Country/Sub-region, 2017–2027

        12.4.1. China

        12.4.2. India

        12.4.3. Japan

        12.4.4. Australia & New Zealand 

        12.4.5. Rest of Asia Pacific 

    12.5. Asia Pacific Recombinant Factor C Assay Market Attractiveness Analysis

        12.5.1. By Brand

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Latin America Recombinant Factor C Assay Market Analysis and Forecast

    13.1.  Key Findings

    13.2.  Latin America Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

        13.2.1. PyroGene

            13.2.1.1. PyroGene Bulk rFC (2,880 tests)

            13.2.1.2. PyroGene rFC (192 tests)

        13.2.2. EndoNext

            13.2.2.1. Endozyme II

            13.2.2.2. Endozyme II GO

            13.2.2.3. EndoLisa

    13.3. Latin America Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

        13.3.1. Pharmaceutical Companies

        13.3.2. Biotechnology Companies

        13.3.3. Medical Device Companies 

        13.3.4. Contract Research Organizations (CROs)

    13.4. Latin America Recombinant Factor C Assay Market Value Forecast, by Country/Sub-region, 2017–2027

        13.4.1. Brazil

        13.4.2. Mexico

        13.4.3. Rest of Latin America 

    13.5. Latin America Recombinant Factor C Assay Market Attractiveness Analysis

        13.5.1. By Product

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

14. Middle East & Africa Recombinant Factor C Assay Market Analysis and Forecast

    14.1.  Key Findings

    14.2.  Middle East & Africa Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027

        14.2.1. PyroGene

            14.2.1.1. PyroGene Bulk rFC (2,880 tests)

            14.2.1.2. PyroGene rFC (192 tests)

        14.2.2. EndoNext

            14.2.2.1. Endozyme II

            14.2.2.2. Endozyme II GO

            14.2.2.3. EndoLisa

    14.3. Middle East & Africa Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027

        14.3.1. Pharmaceutical Companies

        14.3.2. Biotechnology Companies

        14.3.3. Medical Device Companies 

        14.3.4. Contract Research Organizations (CROs)

    14.4. Middle East & Africa Recombinant Factor C Assay Market Value Forecast, by Country/Sub-region, 2017–2027

        14.4.1. GCC Countries

        14.4.2. South Africa

        14.4.3. Rest of Middle East & Africa 

    14.5. Middle East & Africa Recombinant Factor C Assay Market Attractiveness Analysis

        14.5.1. By Product

        14.5.2. By End-user

        14.5.3. By Country/Sub-region

15. Competition Landscape

    15.1. Company Share Analysis

    15.2.   Company Profiles

        15.2.1. Lonza Group

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Financial Overview

            15.2.1.3. Product Portfolio

            15.2.1.4. Strategic Overview

            15.2.1.5. SWOT Analysis

        15.2.2. Hyglos GmbH – a bioMérieux Company 

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Financial Overview

            15.2.2.3. Product Portfolio

            15.2.2.4. Strategic Overview

            15.2.2.5. SWOT Analysis

List of Tables

Table 01: Patent Information – Pyrogene (Lonza)

Table 02: Patent Information – EndoLisa

Table 03: Patent Information – EndoZyme II GO

Table 04: Patent Information – Recombinant Factor C Assay Market

Table 05: Product Features & USPs – Recombinant Factor C Assays

Table 06: Pyrogen Testing- Service Providers

Table 07: Pyrogen Testing- Service Providers

Table 08: Pyrogen Testing Products Marketing

Table 09: Cost per Assay and Turn Around Time (LAL)

Table 10: Institutes Involved in Research Studies using Horseshoe Crabs

Table 11: Institutes Focused on Conversing Horseshoe Crabs

Table 12: Pyrogen Testing Market Offerings, By Company

Table 13: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

Table 14: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

Table 15: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

Table 16: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

Table 17: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Region, 2017–2027

Table 18: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country, 2017–2027

Table 19: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

Table 20: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

Table 21: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

Table 22: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

Table 23: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country/Sub-region, 2017–2027

Table 24: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

Table 25: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

Table 26: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

Table 27: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

Table 28: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country/Sub-region, 2017–2027

Table 29: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

Table 30: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

Table 31: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

Table 32: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

Table 33: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country/Sub-region, 2017–2027

Table 34: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

Table 35: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

Table 36: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

Table 37: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

Table 38: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Country/Sub-region, 2017–2027

Table 39: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by Brand, 2017–2027

Table 40: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by PyroGene, 2017–2027

Table 41: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by EndoNext, 2017–2027

Table 42: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, by End-user, 2017–2027

List of Figures

Figure 01: Global Recombinant Factor C Assay Market Snapshot

Figure 02: Global Recombinant Factor C Assay Market Value (US$ Thousand), by Region, 2018 and 2027

Figure 03: Global Recombinant Factor C Assay Market Value (US$ Thousand) and Y-o-Y (%) Forecast, 2017–2027

Figure 04: Global Recombinant Factor C Assay Market Value Share, by Brand, 2019

Figure 05: Global Recombinant Factor C Assay Market Value Share, by End-user, 2019

Figure 06: Global Recombinant Factor C Assay Market Value Share, by Region, 2019

Figure 07: Value Chain Analysis – Recombinant Factor C Assay Market

Figure 08: Key Industry Events – Recombinant Factor C Assays Market

Figure 09: Regulatory Scenario – North America

Figure 10: Regulatory Scenario – Europe

Figure 11: Regulatory Scenario – Asia Pacific 

Figure 12: Global Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

Figure 13: Global Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

Figure 14: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by PyroGene, 2017–2027

Figure 15: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by EndoNext, 2017–2027

Figure 16: Key Trends – By Brand

Figure 17: Global Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

Figure 18: Global Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

Figure 19: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by Pharmaceutical Companies, 2017–2027

Figure 20: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by Biotechnology Companies, 2017–2027

Figure 21: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by Medical Device Companies, 2017–2027

Figure 22: Global Recombinant Factor C Assay Market Revenue (US$ Thousand) and Y-o-Y Growth (%), by Contract Research Organizations (CROs), 2017–2027

Figure 23: Key Trends – By End-user

Figure 24: Recombinant Factor C Assay Market – Regional Outlook

Figure 25: Global Recombinant Factor C Assay Market Value (US$ Thousand) Forecast, 2017–2027

Figure 26: Global Recombinant Factor C Assay Market Value Share Analysis, by Region, 2018 and 2027

Figure 27: Global Recombinant Factor C Assay Market Attractiveness Analysis, by Region, 2019–2027

Figure 28: North America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 29: North America Recombinant Factor C Assay Market Value Share Analysis, by Country, 2018 and 2027

Figure 30: North America Recombinant Factor C Assay Market Attractiveness Analysis, by Country, 2019–2027

Figure 31: North America Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

Figure 32: North America Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

Figure 33: North America Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

Figure 34: North America Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

Figure 35: Europe Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 36: Europe Recombinant Factor C Assay Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 37: Europe Recombinant Factor C Assay Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 38: Europe Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

Figure 39: Europe Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

Figure 40: Europe Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

Figure 41: Europe Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

Figure 42: Asia Pacific Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 43: Asia Pacific Recombinant Factor C Assay Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 44: Asia Pacific Recombinant Factor C Assay Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 45: Asia Pacific Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

Figure 46: Asia Pacific Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

Figure 47: Asia Pacific Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

Figure 48: Asia Pacific Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

Figure 49: Latin America Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 50: Latin America Recombinant Factor C Assay Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 51: Latin America Recombinant Factor C Assay Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 52: Latin America Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

Figure 53: Latin America Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

Figure 54: Latin America Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

Figure 55: Latin America Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

Figure 56: Middle East & Africa Recombinant Factor C Assay Market Value (US$ Thousand) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 57: Middle East & Africa Recombinant Factor C Assay Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 58: Middle East & Africa Recombinant Factor C Assay Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 59: Middle East & Africa Recombinant Factor C Assay Market Value Share Analysis, by Brand, 2018 and 2027

Figure 60: Middle East & Africa Recombinant Factor C Assay Market Attractiveness Analysis, by Brand, 2019–2027

Figure 61: Middle East & Africa Recombinant Factor C Assay Market Value Share Analysis, by End-user, 2018 and 2027

Figure 62: Middle East & Africa Recombinant Factor C Assay Market Attractiveness Analysis, by End-user, 2019–2027

Figure 63: Global Recombinant Factor C Assay Market Analysis, by Top Company Ranking, 2018

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Recombinant Factor C Assay Market